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background: Alirocumab reduces low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apo B), but its effect on LDL particle (LDL-P) 
and other lipid particle concentrations has not been determined. Standard LDL-C assays measure cholesterol content rather than particle numbers. 
Compared to LDL-C, LDL-P concentration may more closely estimate cardiovascular risk.
methods: This substudy of a Phase II trial (NCT01288443) included patients with LDL-C ≥100mg/dL who received placebo (n=31) or alirocumab 
150 mg administered subcutaneously (SC) every 2 weeks (Q2W) (n=26) on top of stable daily atorvastatin (10-40 mg). Nuclear magnetic resonance 
spectroscopy measured concentrations of total LDL-P, very low-density lipoprotein particles (VLDL-P), high-density lipoprotein particles (HDL-P) and 
lipoprotein subclasses in samples from before and after 12 wks of treatment.
results: The table shows particle concentrations before and after alirocumab 150mg SC Q2W vs placebo. Alirocumab reduced mean LDL-P by 63% 
vs 1% for placebo (P<0.0001) and median VLDL-P by 36% vs a 33% increase for placebo (P<0.0001). HDL-P levels increased 11% for alirocumab vs 
1% for placebo (P<0.05). Changes in all particle subclasses were directionally similar.
conclusions: Alirocumab significantly reduced LDL-P and other lipoprotein particles when added to stable statin therapy with a magnitude of 
reduction similar to its previously reported effect on LDL-C and apo B.
Table. Lipoprotein particle concentrations (nmol/L) for placebo (n=31) and alirocumab 150mg Q2W (n=26). *P<0.05; †P<0.0001 vs. placebo
Mean (sd) or median (Q1:Q3)
Placebo Alirocumab 150 mg Q2W
Baseline Week 12 % change Baseline Week 12 % change
LDL Total LDL 1422.5 (321.3) 1383.8 (327.9) -1.0% 1320 (304.0) 475.4 (167.3)† -63.3%†
Intermediate density lipoprotein 110 (51:166.5) 57 (24.5:144.5) 84.5 (33:115) 37 (12:66)*
Large LDL 546.6 (205.3) 431.8 (217.4) 532.2 (212.9) 152.4 (107.6)†
Small LDL 755.3 (304.9) 847.6 (375.1) 666.5 (333.8) 279.9 (191.0)†
VLDL +chylomicron Total VLDL+chylomicron
61.9 
(47.8:95.6) 83.9 (45:102.2) 33.4%
71.5 
(36.9:94.1)
42.0 
(30.5:54.1)† -36.4%†
Large VLDL
+chylomicron 3.5 (2.1:8.5) 4.3 (1.8:9.4) 3.6 (1.8:8.5) 3.1 (1.7:6.9)
Medium VLDL 19.3 (13.1:33.9)
33.1 
(13.1:51.9) 18.3 (10.7:50) 14.4 (8.2:26.9)†
Small VLDL 35.3 (28.2:47.8)
37.3 
(25.4:56.3) 35.7 (25:49.5)
21.4 
(19.9:26.7)*
HDL Total HDL 32.9 (6.4) 33.2 (7.4) 1.4% 32.6 (6.3) 36.1 (6.5)* 11.2%*
Large HDL 3.8 (2.0) 3.9 (2.2) 4.8 (3.1) 6.1 (3.5)*
Medium HDL 9.2 (5.9:14.4) 8 (5.4:10.2) 7.8 (5.6:10.7) 9.8 (6.6:11.3)
Small HDL 18.8 (5.3) 21.3 (5.8) 19.4 (4.1) 20.0 (5.7)*
